Drug Infusion System Market

Market Overview

The global drug infusion system market share is registering a CAGR of 6.9% during the forecast period (2023-2031). The rise in chronic diseases such as cardiovascular disease, stroke, cancer, type 2 diabetes, obesity, and arthritis drives the drug infusion system market growth.

A drug infusion system is a medical device used to administer fluids, drugs, and therapeutic substances directly into a patient's bloodstream in a controlled and regulated manner. These systems are widely employed in various healthcare settings, such as hospitals, clinics, ambulatory care, and home healthcare. Drug infusion systems are critical in delivering medications and therapies such as chemotherapy, pain management, insulin administration, and antibiotic administration, among others.

The drug infusion system market share is expected to increase during the forecast period due to factors such as increasing prevalence of chronic diseases such as cardiovascular disease, strokes, cancer, type 2 diabetes, and so on, growing geriatric population, technological advancements, rising healthcare expenditure, portability and ease of use, and visual monitoring features. Nonetheless, the high cost of drug infusion systems, a scarcity of experienced professionals, and stringent government regulations are projected to impede market expansion throughout the projection period.

Market Dynamics

Market Drivers

Increasing Prevalence of Chronic Diseases

Chronic disorders, such as diabetes and cancer, are becoming more common, necessitating long-term therapy and precise drug administration. Drug infusion systems aid in the management of various illnesses by delivering drugs in a continuous and controlled manner. Diabetes is a chronic condition that necessitates close monitoring and exact medication administration. Patients frequently require insulin infusion to keep blood glucose levels within the therapeutic range. As the prevalence of diabetes continues to climb, so has the demand for insulin pumps and other drug infusion devices for diabetic care. Patients benefit from better glucose control, which lowers the risk of complications. According to the International Diabetes Federation (IDF), roughly 10.5% of adults (20-79 years) will have diabetes by 2021, with nearly half uninformed that they have it. According to IDF forecasts, one in every eight adults, or roughly 783 million people, will have diabetes by 2045, a 46% rise. 

Furthermore, chronic disorders like cancer frequently necessitate chemotherapy, which may include intravenous (IV) medication infusions. According to the American Cancer Society, around 1.9 million new cancer cases will be identified in the United States alone in 2022. Many of these patients undergo chemotherapy, emphasizing the need for infusion systems. As a result, the Drug Infusion system market trend is projected to be influenced by these disorders.

Market Restraints

High Initial Cost

Drug infusion systems, including infusion pumps and accompanying equipment, can be expensive. This can be costly for healthcare facilities, especially in resource-constrained areas. A fleet of modern infusion pumps, including volumetric and syringe pumps, can cost between USD 5,000 and USD 10,000 per unit. Given the requirement for many units across various departments, the initial cost for a medium-sized hospital with 150 beds can easily approach USD 1 million. According to an American Hospital Association (AHA) report, hospitals in the United States frequently operate on razor-thin financial margins. Hospitals had an average operating margin of 1.9% in 2020. High initial equipment prices might put pressure on already constrained budgets. 

Furthermore, the World Health Organization (WHO) estimates that global healthcare spending will exceed USD 8.3 trillion in 2020. While healthcare spending is significant, healthcare systems must allocate resources across multiple needs, such as personnel, infrastructure, and equipment. System for Drug Infusion According to market research, high upfront expenditures might delay or hinder innovation technology adoption, compromising patient safety and healthcare results. To minimize immediate budgetary problems, facilities may continue to use old equipment.

Market Opportunity

Home Healthcare Expansion

The quest for more accessible and cost-effective treatment options drives the growing trend toward home healthcare. Portable, user-friendly, and home-based drug infusion systems are in high demand. According to a study published in the Journal of Clinical Oncology, patients who received chemotherapy at home reported higher happiness and quality of life than those who received treatment in a hospital setting. Patients value the flexibility and convenience of home-based care, which drives the need for home-use infusion systems.

Furthermore, home treatment can save money for healthcare institutions. According to a National Association for Home Treatment and Hospice (NAHC) survey, home healthcare is frequently less expensive than comparable treatment in hospitals or long-term care institutions. Drug infusion systems that allow for home-based therapy help to save money by lowering hospital admissions and associated costs. Furthermore, advances in remote patient monitoring technologies allow healthcare personnel to track and regulate drug infusion systems remotely. Patients can communicate with healthcare providers via telehealth and mobile apps, improving home-based infusion therapy's safety and effectiveness.

Regional Analysis

The global drug infusion system market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global drug infusion system market shareholder and is estimated to grow at a CAGR of % over the forecast period due to the region's increasing prevalence of chronic diseases. The region's increased prevalence of chronic diseases such as cancer, diabetes, and cardiovascular problems is a major reason driving the strong demand for drug infusion systems to dispense drugs appropriately. The aging population in North America is the second reason driving market revenue growth, as older people frequently require specialized care and long-term drug delivery, necessitating infusion pumps and systems. According to the Heart Disease and Stroke Statistics 2018, cardiovascular disease was responsible for 836,546 deaths in the United States. The significant prevalence of cardiovascular disorders in this region fuels market expansion.

Furthermore, the development of smart pumps and integrated technologies that improve patient safety and treatment outcomes, together with the region's continued focus on technical breakthroughs and advances in healthcare, is driving market revenue growth in this region. Furthermore, as these companies debut new products and enhance their market share, the country's established healthcare infrastructure and the existence of big industry competitors are boosting market revenue growth in this region. 

Europe is expected to expand significantly during the forecast period. The rising prevalence of chronic disease, rising healthcare expenditure, and rising healthcare activities are driving the expansion of this market in Europe. According to the Organization for Economic Cooperation and Development (OECD), chronic disease killed 550,000 working-age persons in European Union countries in 2016. The market is likely to grow because of this region's high frequency of chronic disease. Furthermore, the goal of healthcare practitioners to improve patient safety and treatment outcomes is driving market revenue growth in Europe through a focus on technological upgrades and the development of novel infusion devices. Finally, as these companies debut new products and enhance their market share in Europe, the region's developed healthcare system and the existence of large market competitors are boosting market revenue growth.

Asia-Pacific was predicted to be the fastest-expanding region for the drug infusion system market. Infusion devices are widely utilized to inject insulin into patients' bodies. Diabetes' rising prevalence has an impact on the market in this region. According to the Asian Diabetes Prevention Initiative, Asia has 60% of the world's diabetes population. The rapid urbanization and developing healthcare infrastructure in various APAC nations drive the demand for novel medical devices, particularly medication infusion systems. Second, the prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders is rising, driving market revenue growth. These illnesses necessitate precise and effective drug administration via infusion pumps and systems. This drives the expansion of the market in this region.

The Middle East and Africa have the smallest proportion of the worldwide Drug infusion system market Because of strict government laws and underdeveloped economies. However, this region's increased investment by private market players can promote market growth.

Segmental Analysis

The global drug infusion system market is segmented based on product type, application, Mode of administration, end-user, and region.

Product type is further segmented into Elastomeric infusion systems, disposable infusion systems, syringe infusion systems, peristaltic pumps, multi-channel pumps, patient-controlled analgesia (PCA) pumps, insulin pumps, and implantable infusion systems.

Disposable Infusion Systems occupied the maximum share of the market. Disposable infusion systems are single-use devices that give drugs, fluids, or nutrients intravenously. To avoid cross-contamination, these systems are discarded after a single usage. In hospitals, disposable infusion systems are routinely used for hydration, medicine administration, and blood transfusions.

Elastomeric infusion systems are disposable, portable devices that give medication at a set rate for a set amount of time. They rely on the flexibility of a balloon-like reservoir to gently infuse the drug.

The segment can be bifurcated by application into Oncology/Chemotherapy, Diabetes, Analgesia, Nutrition, Hematology, and Pediatrics.

Oncology/Chemotherapy holds the largest share in the market. In oncology and chemotherapy, drug infusion systems are widely utilized to administer anticancer drugs. These technologies ensure that chemotherapy medications are delivered precisely and controllably to cancer patients. Oncology infusion systems are essential for administering chemotherapeutic drugs, targeted treatments, and immunotherapies to cancer patients.

Infusion devices are important in diabetes management by delivering insulin to diabetic patients. Insulin pumps are a prominent infusion system that keeps blood glucose levels within normal limits.

Based on the Mode of Administration, the market is sub-segmented into Intravenous, Subcutaneous, Arterial, and Epidural.

Intravenous is the major Mode of administration in the market. Intravenous drug infusion is the administration of drugs or fluids directly into a patient's bloodstream via a vein. Many drugs are administered via IV infusion, which allows rapid and exact drug delivery.

The injection of pharmaceuticals or fluids into the fatty tissue layer just beneath the skin is known as subcutaneous drug infusion. Subcutaneous infusion is often slower than IV infusion and is appropriate for drugs that can be absorbed through the skin.

The market is classified into Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers based on end-users.

Hospitals led the market growth. Hospitals are the main healthcare facilities that offer a wide range of medical services, such as acute care, surgery, and specialist therapies. Drug infusion systems are widely used in hospitals for various medical operations and patient care. In hospitals, drug infusion systems are used for chemotherapy, surgical care, intensive care, normal ward care, and various medical illnesses requiring medicine or fluid administration.

Ambulatory Surgical Centers (ASCs), often known as outpatient surgery centers, are medical institutions that specialize in delivering outpatient surgical and procedural treatments to patients. These facilities perform surgeries and medical procedures that do not necessitate an overnight stay in the hospital.

Recent Developments

• September 2023- Medtronic Diabetes received a CE Mark for its new SimpleraTM CGM, which features a disposable all-in-one design.
• September 2023- The European Commission authorized Fresenius Kabi's biosimilar Tyenne®* as the first tocilizumab biosimilar.